This website will be intermittently unavailable on Saturday, 05/18/2024, for scheduled maintenance.

x

INDICATION

Neulasta® (pegfilgrastim) is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. Read More

Neulasta Onpro

CREATE A NEW ACCOUNT

Account Information

Please complete the information below to create an account. If you already have an account and would like to log in, click here.
* Indicates a required field.

Create Login